Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced updated data for povetacicept (pove) in IgA nephropathy ...

Vertex Resource Group Ltd. ("Vertex" or the "Company") reports its financial and operational results for the third quarter ...

CRISPR Therapeutics AG is rated a Buy with $1.9B cash, prudent management, and undervalued shares. Learn more about CRSP ...

Good morning, everyone. My name is Dina Elmonshed, one of the U.S. biotech analysts here at UBS. And joining me today is the President and CEO of Vertex Pharmaceuticals, Reshma Kewalramani. Thank you ...

Povetacicept is an investigational dual BAFF and APRIL inhibitor being tested for various glomerulonephritis types in clinical trials.

Thankfully, some companies can handle an inflationary environment and perform well throughout, while still registering the 12 ...

Intellia Therapeutics NTLA is currently advancing two late-stage in vivo pipeline candidates – nex-z (or, NTLA-2001) for ...

Stifel: Analyst Paul Matteis adjusts the target price from $494 to $445, maintaining a hold rating. This mixed bag of ratings illustrates the cautious optimism surrounding Vertex Pharmaceuticals, as ...

For the quarter ended September 30, Vertex Pharmaceuticals reported adjusted earnings of $4.80 per share, marking an increase from $4.38 in the same quarter last year. This positive performance not ...

These data were presented today during a late-breaking session at the American Heart Association (AHA) Scientific Sessions and published simultaneously in The New England Journal of Medicine (NEJM) in ...

If you're an individual retail investor searching for healthcare stocks you can buy and hold for at least 20 years, here are ...